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Abstract: BACKGROUND Malignant serous effusion (MSE) denotes a manifestation of metastatic dis-
ease with typical high concentrations of both cancer and immune cells, making them an ideal resource for
in vitro cytologic studies. Hence, the aim of the study was to investigate the features of 2D and 3D MSE
culture systems as well as their feasibilities for in vitro drug screening. METHODS Pleural and peritoneal
effusions from 8 patients were collected and processed for 2D monolayer and 3D hanging drop cell culture
into GravityPLUS™ plates. Representative markers for cell components, proliferation rate and tumour
classification were investigated by immunohistochemistry, followed by absolute quantification using a dig-
italised image analysis approach. Further, we implemented another 3D cell culture model based on a low
attachment method for in vitro drug sensitivity testing of carboplatin, pemetrexed and pembrolizumab
for 5 patients. RESULTS Monolayer cell culture was favourable for the growth of mesothelial cells, while
hanging drop culture in GravityPLUS™ plates showed better ability for preserving cancer cells, induc-
ing positive diagnostic markers expression and restraining the growth of mesothelial cells. For in vitro
drug testing, MSE from five patients presented various drug sensitivities, and one case showed strong
response to PD-1 checkpoint inhibition (pembrolizumab). For some patients, the application of combi-
natorial drugs had better therapeutic responses compared to monotherapy. CONCLUSIONS Digitalised
quantification of data offers a better understanding of different MSE culture models. More importantly,
the proposed platforms are practical and amenable for performing in vitro chemo-/immunotherapeutic
drug testing by using routine cytologic MSE in a personalised manner. Next to cell blocks, our work
demonstrates the prognostic and predictive value of cytologic effusion samples.
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Abstract 
Background: Malignant serous effusion (MSE) denotes a manifestation of metastatic disease with typical high 
concentrations of both cancer and immune cells, making them an ideal resource for in vitro cytologic studies. Hence, 
the aim of the study was to investigate the features of 2D and 3D MSE culture systems as well as their feasibilities for 
in vitro drug screening.
Methods: Pleural and peritoneal effusions from 8 patients were collected and processed for 2D monolayer and 3D 
hanging drop cell culture into GravityPLUS™ plates. Representative markers for cell components, proliferation rate and 
tumour classification were investigated by immunohistochemistry, followed by absolute quantification using a digi‑
talised image analysis approach. Further, we implemented another 3D cell culture model based on a low attachment 
method for in vitro drug sensitivity testing of carboplatin, pemetrexed and pembrolizumab for 5 patients.
Results: Monolayer cell culture was favourable for the growth of mesothelial cells, while hanging drop culture in 
GravityPLUS™ plates showed better ability for preserving cancer cells, inducing positive diagnostic markers expres‑
sion and restraining the growth of mesothelial cells. For in vitro drug testing, MSE from five patients presented various 
drug sensitivities, and one case showed strong response to PD‑1 checkpoint inhibition (pembrolizumab). For some 
patients, the application of combinatorial drugs had better therapeutic responses compared to monotherapy.
Conclusions: Digitalised quantification of data offers a better understanding of different MSE culture models. More 
importantly, the proposed platforms are practical and amenable for performing in vitro chemo‑/immunotherapeutic 
drug testing by using routine cytologic MSE in a personalised manner. Next to cell blocks, our work demonstrates the 
prognostic and predictive value of cytologic effusion samples.
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Background
Heart failure, infection and malignancy are the main 
causes of serous effusions [1]. The conventional smear 
(CS) and cell block (CB) methods are commonly used for 
cytologic diagnosis of exudative serous effusions [2], and 
cytopathologists frequently use these tools for gaining 
immediate information regarding malignancy or specific 
infection in patients in which organ biopsies are difficult 
to perform. Patients bearing malignant serous (pleural 
and peritoneal) effusions have diverse median overall 
survivals between 4 and 9  months depending on can-
cer entity [3–5]. Etiologically, adenocarcinomas of lung, 
breast, ovary as well as mesothelioma are the most fre-
quent cancer entities that metastasise to the pleural and 
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In the MSE, cancer-associated cells such as activated 
mesothelial cells and immune cells could promote and 
support cancer cell survival and proliferation without the 
need of stromal cells. Thanks to the abundant access to 
ligands and growth factors, malignant cells in MSE can 
spread and metastasise to adjacent sites [7]. These cells 
are usually creating a pro-inflammatory environment 
enriched in cytokines and growth factors promoting a 
permissive local microenvironment for metastatic pro-
cesses. With the prominent intratumoural heterogeneity, 
MSE is capable of driving disease progression towards an 
invasive phenotype [8]. We have previously shown that 
patients bearing malignant pleural effusions were char-
acterised by heterogeneous expression of immune cells 
and immunomodulators in their effusion liquids, which 
resulted in different prognosis [9].
Chemotherapy by intracavitary administrating of anti-
cancer drugs is a common method for treating MSE 
[10–12]. However, only modest gains have been made in 
long-term patient survival due to multidrug-resistant and 
highly aggressive characteristics of tumours growing in 
either pleural or peritoneal cavity. Screening of patients’ 
own samples for in  vitro chemo/immunotherapeutic 
agent selection enables the optimisation of individual 
therapeutic regimens [13]. To date, the utilisation of MSE 
2D cell culture for drug screening and other experimen-
tal studies has already been demonstrated from literature 
evidences [8, 13, 14]. Moreover, in vitro MSE models gen-
erated either with scaffold-free techniques or with hydro-
gel matrix support were also used in few studies [15, 16]. 
There are still some efforts that need to be done, such as 
to better retain tumour heterogeneity and cellular com-
ponents, and to establish a more robust and standardised 
platform for preclinical testing.
Therefore, the aim of our study was to perform a cyto-
logic analysis using a digital image analysis approach to 
investigate the alterations of diagnostic marker profiles, 
cell components and cell proliferation rates of MSE in 2D 
and 3D cell cultures. Ultimately, we wanted to evaluate 
the feasibility of MSE models for personalised drug test.
Methods
Collection and processing of cells
Only MSE with unequivocal diagnostic results from the 
department of pathology were accepted including the 
tumour types of lung adenocarcinoma (LADC), breast 
carcinoma (Breast-Ca), ovarian carcinoma (Ovarian-
Ca), gastro-intestinal carcinoma (GIT-Ca) and mela-
noma. After centrifugation the supernatant was removed 
and preserved. The cellular sediment was resuspended 
with the RPMI 1640 culture medium (Gibco, Waltham, 
MA, USA) followed by a cell-counting step using Nucle-
oCounter (ChemoMetec, Denmark).
For 2D cell culture, 1 million cells were cultured in a 
T-25 culture flask (Corning, NY, USA) in an incubator at 
37 °C and 5%  CO2 with 10 ml complete culture medium 
RPMI 1640 with 10% fetal calf serum (FCS, Gibco) and 
Antibiotic–Antimycotic® (Gibco). The medium was 
replaced every 3–5 days. After reaching 70–80% conflu-
ence, the cells were harvested by incubation with TrypLE 
Express (Gibco) for up to 5 min at 37 °C.
For 3D hanging drop culture, GravityPLUS™ plates 
(InSphero, Schlieren, Switzerland) were used as 
described previously [17]. Briefly, MSE cells were seeded 
at a density of 1000 cells per drop and co-cultured with 
normal human dermal fibroblasts (nHDF) at a ratio of 1:1 
in an InSphero Proprietary medium at 37 °C and 5%  CO2. 
After 2–4 days of spheroid formation, microtissues were 
transferred into GravityTrap™ ULA plates (InSphero) for 
further analysis.
For the low-attached 3D cell culture, the cell pellet was 
resuspended in 50% of complete culture medium and 
50% MSE supernatant and seeded in a cell culture dish 
(100 mm). Since MSE samples were normally preserved 
at 4  °C before processing, we put the dish at 37  °C and 
5%  CO2 in the incubator for 24 h on a rotator (30 rpm) to 
mimic the motion as the MSE cells would experience in 
the patient’s cavity. Afterwards, the cells were dispensed 
into a 96 well plate with ultra-low attachment surface 
(Corning) at a density of 7000 cells per well in complete 
culture medium overnight, for further in  vitro drug 
screening assays.
Cell blocks and immunohistochemistry (IHC)
Cell pellets from harvested 2D cultured cells and origi-
nal MSE effusions were prepared and processed to make 
cell blocks as previously described [18]. Briefly, cell pel-
lets were supplemented with thrombin and plasma for 
clot formation. After 4% para-formaldehyde fixation for 
1 h at 4 °C, clots were paraffin-embedded and haematox-
ylin-eosin (H&E) stained. Microtissues were collected in 
1.5  ml tubes and washed once with PBS. Consequently, 
they were fixed in 4% para-formaldehyde for 1 h at 4 °C. 
Fixed microtissues were collected in the tip of a 1.5  ml 
microtube, embedded in 2% agarose (Amresco, Solon, 
OH) and covered with PBS. For paraffin-embedding, the 
agarose plugs were taken out of the microtubes and the 
tip containing the microtissues was cut and placed in 
formalin for 12–14  h, followed by gradual dehydration. 
Finally, the plugs were embedded in paraffin (microtis-
sues facing downwards) in order to facilitate sectioning.
For IHC analysis, Sects.  (3  μm) were prepared and 
stained for antibodies against CD3 (T cells), CD45 
(immune cells), Pan-CK (epithelial tumour cells), cal-
retinin (mesothelial cells), MIB-1 (cell proliferation 
marker), and diagnostic markers for each MSE tumour 
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entity: thyroid transcription factor 1 (TTF-1, LADC), 
CDX2 (GIT-Ca), estrogen receptor (ER, Breast-Ca and 
Ovarian-Ca), melan-A and S100 (melanoma) were per-
formed on a Benchmark Ultra platform (Roche, Ventana 
Medical Systems, Oro Valley, AZ, USA) with proto-
cols used for routine diagnostics. PD-L1 antibody clone 
E1L3N (Cell Signaling Technology, Danvers, MA, USA) 
was used. PD-L1 immunoreactivity was dichotomised 
into low (0 to 49%) and high (≥ 50%), taking into account 
only membranous staining of tumour cells. Diagnostic 
markers were scored 0 (negative −) or 1 (positive +). All 
primary antibodies used for IHC analysis were listed in 
Additional file 2: Table S1.
Digital image analysis
Immunohistochemically stained sections were scanned 
with a high-resolution whole-slide scanner (Hamamatsu 
Nanozoomer Digital Pathology) using a ×40 objec-
tive with spatial resolution of 0.23  µm/pixel. As for the 
colour-based segmentation, IHC results were quantified 
using ImageJ software (National Institutes of Health, 
USA, version 1.47t), which could separate positive 
stained areas (brown/red) from non-stained areas (blue/
grey) by colour thresholding using the Lab colour space. 
Fixed thresholds were used for each set of images. The 
ratio of positive pixels to the total number of pixels per 
image was quantified (n = 3).
In vitro drug test
Drug efficacy test was applied only to the low attached 
cell culture systems. Drug sensitivities of carboplatin 
(Sigma-Aldrich, St. Louis, MO, USA), pemetrexed 
(Santa Cruz Biotechnology, Dallas, TX, USA) and pem-
brolizumab  (KEYTRUDA®, Merck & Co., USA) were 
evaluated. There were six testing groups including (1) 
carboplatin (50 µM), (2) pemetrexed (5 µM), (3) pem-
brolizumab (2.5  nM), (4) carboplatin (50  µM) + pem-
etrexed (5 µM), (5) carboplatin (50 µM) + pemetrexed 
(5  µM) + pembrolizumab (2.5  nM) and (6) control 
group (complete culture medium only), (n = 4). After 
incubation for 48  h, cell proliferation was assessed 
using CCK-8 kit (Dojindo, Japan). Briefly, 10  µl of 
CCK-8 was added into each testing well (containing 
100  µl medium), followed by incubation for one hour 
at 37  °C and 5%  CO2. The optical density was deter-
mined using a spectrophotometer (Infinite F Plex, 
Tecan, Switzerland) at 490  nm with background cor-
rection at 630 nm.
Statistical analysis
All data were expressed as mean ± SD. All statistical anal-
yses were performed on SPSS software, version 23 (IBM, 
USA) or environment R, version 3.4.2 (R Core Team). 
Results were analysed with Student’s T test and p-val-
ues < 0.05 were considered statistically significant.
Results
Cohort description
We received 17 malignant effusions from pleura or 
ascites, among which 13 samples (Table  1) fulfilled 
the standards for proper cell cultures. Samples from 
patients 1 to 8 (P1 to P8) were used for 2D and 3D hang-
ing drop cell cultures, and subsequently analysed for the 
Table 1 Cohort description
TTF-1 thyroid transcription factor 1, ER estrogen receptor, LADC lung adenocarcinoma, Breast-Ca breast carcinoma, Ovarian-Ca ovarian carcinoma, GIT-Ca 
gastrointestinal carcinoma, + positive, − negative
Case Location Age Sex Tumour type Diagnostic markers Volume (ml) Cell count 
(M/ml)
Drug test
1 Pleura 60 Male GIT‑Ca CDX2+ 45 2.3 No
2 Pleura 56 Male Melanoma Melan‑A+ 2600 2.5 No
3 Pleura 71 Female GIT‑Ca CDX2+ 2000 4.2 No
4 Ascites 67 Male GIT‑Ca CDX2+ 1800 0.6 No
5 Ascites 46 Female Breast‑Ca ER+ 600 6 No
6 Ascites 68 Female Melanoma Melan‑A−, S100+ 2000 1.4 No
7 Pleura 43 Male GIT‑Ca CDX2+ 1200 0.38 No
8 Pleura 92 Male LADC TTF‑1+ 800 0.38 No
9 Pleura 54 Female LADC TTF‑1+ 1600 0.03 Yes
10 Ascites 68 Female Ovarian‑Ca ER+ 2500 0.08 Yes
11 Pleura 43 Female Ovarian‑Ca ER+ 1100 0.12 Yes
12 Pleura 72 Male LADC TTF1− 1500 0.5 Yes
13 Pleura 65 Female Breast‑Ca ER+ 2000 0.4 Yes
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expression of markers to discriminate the different cell 
components. Samples P9 to P13 were processed only for 
in vitro drug testing. Clinical information together with 
sample volume and cell concentration for each effusion 
















Scale bar = 200 µm
Rotator 30 rpm
20µm
MSE GIT-Ca MSE melanoma
Fig. 1 Malignant serous effusions (MSE) 2D and 3D cell culture and drug screening system. a conventional 2D monolayer cell culture system, scale 
bar = 500 µm. b 3D hanging drop cell culture system (modified from InSphero Product Manual of GravityPLUS™ Hanging Drop System with the 
permission from InSphero AG). For the two show cases of MSE stomach adenocarcinoma and skin melanoma, the ratio indicated the number of 
MSE cells to normal human dermal fibroblasts (nHDF), scale bar = 200 µm. c drug screening platform using low attached cell culture system, scale 
bar = 50 µm (left) or 20 µm (right), respectively. CM conditional medium
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Establishing MSE in vitro cell culture systems
We investigated one conventional 2D cell culture and two 
3D cell culture systems. After 2D cell culture of MSE over 
10 to 14 days, cells reached 70–80% confluence (Fig. 1a). 
3D hanging drop cell culture system offered an efficient 
approach for microtumour formation (diameter around 
200 µm) with the help of nHDF to provide physical sup-
port and enhance cellular spheroids assembly. Several 
ratios of MSE cells and nHDF have been tested with the 
final indication of 1:1 as the optimal one. MSE cells could 
not form compact microtissue without the support of 
nHDF (Fig. 1b). In order to reproduce the microenviron-
ment of MSE in  vivo conditions, we created a platform 
containing a rotation process, following floating cell 
cultures using ultra low attachment wells (Fig. 1c). Con-
sidering the short half-life of immune cells and the time 
needed for potential clinical applications, the drug test 
was only performed for 48 h. There were cell clots float-
ing in the medium, which were surrounded by several 
single cells.
H&E, immunohistochemistry and digital image analysis
The histological analysis based on cell types, cell pro-
liferation and diagnostic markers are shown in Fig.  2 
(showcase of P2, melanoma). The IHC yielded good 
immunoreactivity performance with clear background 
for all markers investigated. However, 2D and 3D cul-
ture systems had a different impact on the expression of 
IHC markers and the overall cell growth rate. In order to 
quantify these marker expressions, we performed digi-
talised image analysis (showcase P2, Fig.  3a). The posi-
tive staining area (red) recognised by colour thresholding 
using the “Lab” colour space was annotated in yellow; 
non-staining area (blue/grey) was annotated in purple. 
Other IHC stainings with positive area in brown were 
processed similarly (Additional file 1: Fig. S1).
Comparison of cellular components, cell proliferation 
and diagnostic markers expression between 2D and 3D cell 
culture systems
Histological analysis of cell types, cell proliferation and 
diagnostic marker expression were quantified and pre-
sented as the ratio of positive pixels to the total number 
of pixels per image (Fig. 3b, Additional file 2: Table S2). 
Overall, 2D culture condition sustained the growth of 
mesothelial cells (calretinin) and poorly supported the 
retainment of diagnostic markers (P2, P4 and P7). By 
contrast, 3D hanging drop culture showed better pres-
ervation of cancer cells with positive diagnostic marker 
expression (P2, P5 and P6). However, both culture sys-
tems were not suitable for the growth of immune cells, 
with poor-negative staining for CD45. Additionally, 2D 
culture condition was more favourable to the general cell 
growth.





















Fig. 2 Comparison of H&E and expression of representative markers for cell types, diagnosis and proliferation. Original melanoma MSE and the 
respective 2D and 3D cell cultures were compared. Pan‑CK (tumour cells), CD45 (immune cells) and calretinin (mesothelial cells) positive expression 
can be visualised in brown stain. Double staining of Melan‑A (melanoma diagnostic marker) and MIB‑1 (proliferation marker) are detected, 
respectively, in red and brown stains, scale bar = 100 µm
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In vitro drug sensitivity test of MSE with chemotherapeutic 
agents and PD‑1 blockade with immunomodulatory drug
As shown in Fig. 4a, patients responded heterogeneously 
to traditional chemotherapeutic agents at the testing 
concentration levels. Especially, upon administration of 
carboplatin and pemetrexed, cases P9 and P13 were the 
most affected with high level of cytotoxicity. In contrast, 
P10, P11 and P12 were more sensitive only to carbopl-
atin, showing a strong impairment in cell proliferation, 
whereas pemetrexed had only minor effect to the cells. 
Notably, combinatorial treatment with carboplatin and 
pemetrexed displayed higher cytotoxic effect in P12 and 
P13 rather than in single drug treatment regimens.
For the applications of immunotherapy treatment 
based on pembrolizumab, P9 was selected as the best 
case, showing a positive therapeutic response with a 
remaining 40% of cell viability, while other patients 
(P13 was slightly significant) did not show significant 
sensitivity towards the biological treatment. Moreover, 
all five malignant effusions were highly infiltrated by 
 CD3+ T cells (original cell blocks, Fig. 4b, the quantifi-
cation result in Additional file 2: Table S3). In addition, 
PD-L1 was heterogeneously expressed, with high level 
in P12 and P10 (non-membranous positive staining) 
and low level in P9, P11 and P13 (Fig. 4b). Furthermore, 


























































































































Overall stained area: 29%a
b
Fig. 3 Quantification of IHC staining. a Digitalised image analysis approach of IHC staining, a showcase of Melan‑A IHC. Melan‑A staining of 
the showcase (P2) sample in 3D hanging drop cell culture. The positive staining area (red) recognised by colour thresholding using the “Lab” 
colour space was annotated in yellow; non‑staining area (blue/grey) was annotated in purple, scale bar = 200 µm. b Quantification of expressed 
histological markers for proliferation, diagnosis and representative cellular components in original MSE, 2D and 3D hanging drop cell cultures. The 
ratio (percentage) of positive pixels to the total number of pixels of each marker was presented
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and pemetrexed) with biologic anti-PD-1 pembroli-
zumab considerably enhanced the cytotoxicity in P9 
compared to treatment with only small molecules. This 
specific outcome was not observed in any of the other 
samples.






















































































































































Fig. 4 In vitro drug sensitivity test using low attached 3D cell culture system. a MSE samples were treated with carboplatin (50 µM), pemetrexed 
(5 µM) and pembrolizumab (2.5 nM) in a single or combinatorial manner, N = 4. Cell proliferation readout of each group was shown as value ± SD 
compared with the corresponding vehicle group (control group). *p‑value < 0.05 other groups compared with the control group; #p‑value < 0.05 
combinatorial test groups compared with Carbo and Peme test groups; ∆p‑value < 0.05 C + P + Pembro triple test group compared with C + P 
combinatorial test group. b PD‑L1, CD3 and diagnostic (Dx) marker staining of original cell blocks, scale bar = 100 µm. Arrow: tumour cell. 
Abbreviations: carboplatin (carbo, C), pemetrexed (peme, P), pembrolizumab (pembro)
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Discussion
We propose our in  vitro drug screening platform from 
MSE material as reliable alternative to invasive in  vivo 
research with increased cost effectiveness. The MSE sys-
tem enables the assessment of several chemotherapeutic 
and biological drugs already approved and it can be con-
sidered as immediate biological tool for exploring novel 
therapeutic approaches.
However, the current preclinical models are not suffi-
ciently developed to account for the intratumoural het-
erogeneity and inter-patient variability [19]. Therefore, 
we first investigated 2D and 3D hanging drop cell culture 
systems using MSE samples from several cancer entities 
and studied their features. According to the literatures, 
monolayer cell cultures show some weakness related to 
the overgrowth of fibroblast (solid tumour), long cul-
turing time and loss of cancer cell heterogeneity [19, 
20]. In our study, despite the high growth rate and high 
component of Pan-CK positive cells of 2D cell cultures, 
most of the cells lost the tumour phenotype. Research 
from Ordóñez N.G. shows that nearly all mesothelial 
cells (including mesotheliomas) can be positive for pan-
cytokeratin (Pan-CK) (including AE1/AE3) [21]. There-
fore, for MSE cytologic diagnosis, Pan-CK is not be a 
proper marker for recognising tumour cells. Clearing of 
mesothelial cells using magnetic cell separation (MACS 
systems) might be crucial to establish pure cultures of 
MSE to be used for screening assays [13].
The optimal growth conditions observed in 3D cell cul-
tures supported the proliferation of tumour cells with a 
more reduced presence of mesothelial cells. The pro-
portion of cells expressing diagnostic markers was also 
higher than corresponding 2D culture mirroring the 
histological analysis of the original MSE samples. The 
use of 3D Gravity plates enables high throughput chemo 
drug screening, and it allows specific functional studies 
involved in cancer progression. Despite these advantages, 
MSE as a liquid biopsy will require a fibroblast compo-
nent for an easier cell aggregation in a 3D structure. 
As both 2D and 3D hanging drop systems lost immune 
cell viability for the necessary screenings, we thereafter 
established the drug testing platform with a processing 
time less than 4 days. It mirrored the floating cells culture 
property of MSE microenvironment, which might better 
preserve the viability of immune cells and augment the 
chance for tumour–immune cells interaction.
Carboplatin and pemetrexed were selected for the ther-
apeutic drug-testing assay, as they are frequently used in 
the treatment of lung adenocarcinoma, breast cancer and 
mesothelioma. In addition, we tested the anti-PD-1 drug 
pembrolizumab, which has been widely used for many 
metastatic cancer therapies [22, 23]. Drug concentra-
tions were selected and designed according to available 
scientific information (125514Orig1s000, FDA pembroli-
zumab in  vitro IC50 test) [24, 25]. Different grades of 
sensitivity were observed in all patients following single 
or combinatorial drug treatments. Interesting, most of 
our in vitro outcome could be positively correlated with 
the benefits of current therapeutic approaches based on 
the simultaneously targeting of different signalling path-
ways and empowering the immune system using differ-
ent immunomodulators [26–28]. In our investigation, we 
could not observe any upregulation of PD-L1, which is 
refereed as a predictive marker to screen patients for the 
applications of immunotherapy.
Further open questions are to be addressed concerning 
the pembrolizumab efficacy and function in this system, 
given the fact that a direct co-culture with patient’s autol-
ogous lymphocytes is difficult to achieve, and the optimi-
sation of digitalised image analysis, which was conducted 
based on pixels but not cell counts in our study.
Conclusion
Our first data encourage and prompt us towards further 
investigation of MSE to uncover complex mechanisms of 
drug action, while the system provide a good platform 
for selection of drug candidates. Culture of MSE in 3D 
structure better reflects the original cell composition and 
functions, therefore offering a better clinical translation 
of in vitro observations.
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